ELAN Elanco Animal Health Inc
Pharmaceutical Preparations · NYSE · SEC CIK 1739104 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY12.1%
TTM net income YoY-508.3%
TTM EPS YoY-528.6%
Revenue 3-yr CAGR5.7%
Net income 3-yr CAGR—
Margins
Gross margin56.2%
Operating margin—
Net margin-2.9%
FCF margin7.9%
EBITDA margin—
Returns
ROE-2.2%
ROA-1.1%
ROIC (approx.)—
Asset turnover0.38x
Leverage & solvency
Liabilities / assets50.3%
Debt / equity0.56x
Current ratio2.09x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-4.18x
Accruals ratio-5.7%
Payout ratio—
Capex / revenue4.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $4.71B | $4.44B |
| Cost of revenue | $2.12B | $2.00B |
| Gross profit | $2.59B | $2.44B |
| R&D expense | $368.00M | $344.00M |
| SG&A expense | $1.43B | $1.31B |
| Pretax income | -$224.00M | $488.00M |
| Income tax | $8.00M | $150.00M |
| Net income | -$232.00M | $338.00M |
| EPS (basic) | -0.47 | 0.68 |
| EPS (diluted) | -0.47 | 0.68 |
| Weighted avg. shares (diluted) | 496.40M | 497.30M |
| Balance sheet | ||
| Cash & equivalents | $545.00M | $468.00M |
| Receivables | $873.00M | $805.00M |
| Inventory | $1.74B | $1.57B |
| Current assets | $3.46B | $3.21B |
| PP&E, net | $1.41B | $993.00M |
| Goodwill | $4.78B | $4.41B |
| Intangibles | $3.41B | $3.68B |
| Total assets | $13.36B | $12.61B |
| Current liabilities | $1.60B | $1.31B |
| Short-term debt | $74.00M | $44.00M |
| Long-term debt | $3.94B | $4.28B |
| Total debt | $4.02B | $4.32B |
| Total liabilities | $6.81B | $6.52B |
| Shareholders' equity | $6.55B | $6.10B |
| Net debt | $3.47B | $3.85B |
| Shares outstanding | 496.98M | 494.45M |
| Cash flow statement | ||
| Operating cash flow | $560.00M | $541.00M |
| Capital expenditure | $276.00M | $147.00M |
| Free cash flow | $284.00M | $394.00M |
| Investing cash flow | -$279.00M | $1.16B |
| Financing cash flow | -$275.00M | -$1.49B |
| Depreciation & amortization | $680.00M | $662.00M |
| Stock-based compensation | $68.00M | $55.00M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.